Drugs / Menjugate
Menjugate
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT01434680 | Sep 2011 → Nov 2012 | meningococcal meningitis | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00310856 | Jun 2005 → Nov 2006 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00262002 | Sep 2004 → Jul 2005 | meningococcemia | Novartis Vaccines | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT01553279 | Mar 2012 → Sep 2013 | meningococcal infection, viral infectious disease | MCM Vaccines B.V. | Completed | No outcome recorded |
| Phase 3 | NCT01359449 | May 2011 → Jul 2012 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01266993 | Jan 2011 → Mar 2014 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00866619 | Mar 2009 → Mar 2011 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00311415 | Oct 2005 → Apr 2008 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00310674 | Sep 2004 → ? | meningococcal infection | Novartis | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT06209398 | May 2018 → Dec 2024 | hand, foot and mouth disease | Jiangsu Province Centers for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase 4 | NCT00625677 | Feb 2008 → Mar 2010 | meningococcal infection, pneumococcal infection | Public Health England | Completed | No outcome recorded |
| Phase 4 | NCT00392808 | Jan 2007 → May 2008 | meningococcal infection | Center for Public Health Research | Completed | No outcome recorded |
| Phase 4 | NCT00310713 | Apr → Aug 2006 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 4 | NCT00310635 | Jun 2005 → ? | meningococcal infection | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00310700 | May → Nov 2005 | meningococcal infection | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00197808 | Apr 2005 → Jan 2010 | meningococcal infection, pneumococcal infection | Public Health England | Completed | No outcome recorded |
| Phase 4 | NCT00316654 | Feb → Oct 2005 | meningococcal infection | Novartis Vaccines | Completed | No outcome recorded |
| Phase 4 | NCT00262015 | Sep 2003 → ? | meningococcal meningitis | Chiron Corporation | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 19 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01889836 Comparator | May → Dec 2014 | meningococcal meningitis | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Completed | No outcome recorded |
| Phase 1 | NCT06165276 Comparator | Jul 2006 → Aug 2008 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT01171989 Comparator | Aug → Dec 2010 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01098474 Comparator | Jul 2010 → Apr 2011 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01090453 Comparator | May 2010 → Oct 2011 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, meningococcal infection +2 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00970307 Comparator | Aug 2009 → Jan 2010 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00871338 Comparator | Jun 2009 → Mar 2010 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00871741 Comparator | Apr → Jun 2009 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, meningococcal infection +2 | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT00381615 Background | Sep 2006 → Jul 2007 | — | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00129116 Comparator | Mar → Dec 2003 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT05969626 Comparator | Aug 2023 → Apr 2024 | rabies | Ningbo Rongan Biological Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02207816 Comparator | Sep 2014 → Jan 2017 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01144663 Comparator | Jul 2010 → Jun 2012 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00674583 Comparator | May → Sep 2008 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00657709 Comparator | Mar 2008 → Jan 2010 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00644059 Comparator | Nov 2007 → Apr 2010 | influenza | Novartis | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05397587 Comparator | Jul 2022 → Jul 2025 | hand, foot and mouth disease | Sinovac Biotech Co., Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT01896596 Comparator | Jul 2013 → Apr 2017 | haemophilus infectious disease, hepatitis B virus infection, meningococcal infection, pneumococcal infection | Public Health England | Completed | No outcome recorded |
| Phase 4 | NCT01693380 Background | May → Jun 2009 | influenza | Butantan Institute | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Menjugate | “Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule.” NCT01359449 ↗ |
| Known as | control vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05969626 ↗ |
| Known as | Enterovirus Type 71 Vaccine, Inactivated（Human Diploid Cell） | “Enterovirus Type 71 Vaccine, Inactivated（Human Diploid Cell）” NCT05397587 ↗ |
| Known as | MCC-CRM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01553279 ↗ |
| Known as | Men C conjugated vaccine | “Menjugate (Men C conjugated vaccine)” NCT00262002 ↗ |
| Known as | MenC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01359449 ↗ |
| Known as | MenC-CRM | “previously primed with 3 doses of a MenC vaccine conjugated with CRM197 (MenC-CRM) or with 2 doses of a MenC vaccine conjugated with tetanus toxoid (MenC-TT), were randomized...” PMID 19927040 ↗ Feb 2010 |
| Known as | Meningococcal C Conjugate Vaccine | “of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered.” NCT01693380 ↗ |
| Known as | Meningococcal Group C-CRM197 Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06165276 ↗ |
| Modality | Vaccine | “Men C conjugated vaccine” NCT00262002 ↗ |
| Route | Intramuscular | “Menjugate was injected IM in the anterolateral area of the right thigh” NCT00262002 ↗ |